Members Obtain Free CE Credits from JCP Articles!

Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease

October 2025 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?
Learners that complete this course will enhance their knowledge on the pharmacokinetics of etrolizumab and assess its exposure–response (ER) relationship for key clinical outcomes in patients with moderately-to-severely active Crohn's disease. This activity was designed to develop pharmacometrics skills and strategies to evaluate the exposure and efficacy of new therapies.

ACPE Accreditation Statement
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
UAN: 0665-0000-25-031-H01-P – ACPE 1 Contact Hours
Activity Type: Knowledge-based **Format:** Home-study **Target Audience**: 'P'

ACCME Accreditation Statement
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement
The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in expanding their knowledge on the pharmacokinetics of etrolizumab in patients with moderately-to-severely active Crohn's disease.

Learning Objectives
After completing this activity, the learner will be able to:

1. Describe the etrolizumab exposure in patients with moderately-to-severely active Crohn's disease using a population pharmacokinetic (PK) model;
2. Identify significant etrolizumab covariate effects of the PK model in patients with moderately-to-severely active Crohn's disease;
3. Evaluate the relationship between etrolizumab exposure and observed response rates in patients with Crohn's disease;
4. Discuss potential confounding factors influencing the response rates during both the induction and maintenance phases of treatment in patients with Crohn's disease.

Requirements to Receive Credit
In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE

Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection:	John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.
Planner:	Kenneth Der, BS, Associate Director, is employed and owns stock in Amgen, planned the continuing education documentation for this course and all of the relevant financial relationships have been mitigated.
CE Reviewer:	Gwendolyn Pais, BPharm, PhD, Research Assistant Professor, Midwestern Univ, served as the CE Reviewer and has nothing to disclose.

Schedule & Fees
JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support
No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates
Date of Issuance: 10/1/2025
Expiration Date: 10/1/2028

Online Location:
https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14